Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 4, July-August, p. 781–787

doi: 10.17219/acem/61914

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The Role of Mast Cells in Alzheimer’s Disease

Yasdani B. Shaik-Dasthagirisaheb1,A,B,C,D,E,F, Pio Conti2,A,B,C,D,E,F

1 Department of Medicine, Boston University School of Medicine, Boston, USA

2 Immunology Division, Postgraduate Medical School, University of Chieti-Pescara, Chieti, Italy

Abstract

Immunity and inflammation are deeply involved in Alzheimer’s disease. The most important properties of pathological Alzheimer’s disease are the extracellular deposits of amyloid â-protein plaque aggregates along with other unknown mutated proteins, which are implicated in immunity and inflammation. Mast cells are found in the brain of all mammalian species and in the periphery, and their biological mediators, including cytokines/chemokines, arachidonic acid products and stored enzymes, play an import role in Alzheimer’s disease. Cytokines/chemokines, which are generated mostly by microglia and astrocytes in Alzheimer’s disease, contribute to nearly every aspect of neuroinflammation and amyloid â-protein plaque aggregates may induce in mast cells the release of a plethora of mediators, including pro-inflammatory cytokines/chemokines such as interleukin-1, interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-alpha, vascular endothelial growth factor, transforming growth factor beta, CXCL8 and CCL2-3-4. These proinflammatory cytokines/chemokines are prominent mediators of neuroinflammation in brain disorders such as Alzheimer’s disease, and their inhibition may be associated with improved recovery. In this review, we summarize the current knowledge regarding the roles of mast cell mediators (stored and de novo synthesis) in the pathogenesis of Alzheimer’s disease.

Key words

inflammation, immunity, mast cell, Alzheimer’s disease

References (46)

  1. Querfurth HW, LaFerla FM: Alzheimer’s disease. N Engl J Med 2010, 362, 329–344.
  2. Licastro F, Carbone I, Raschi E, Porcellini E: The 21st century epidemic: Infections as inductors of neuro-degeneration associated with Alzheimer’s Disease. Immun Ageing 2014, 11, 22.
  3. Nussbaum RL, Ellis CE: Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003, 348, 1356–1364.
  4. Qahwash I, Weiland KL, Lu Y, Sarver RW, Kletzien RF, Yan R: Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. J Biol Chem 2003, 278, 23187–23195.
  5. Serpente M, Bonsi R, Scarpini E, Galimberti D: Innate immune system and inflammation in Alzheimer’s disease: From pathogenesis to treatment. Neuroimmunomodulation 2014, 21, 79–87.
  6. Venturini L, Perna S, Sardi F, Faliva MA, Cavagna P, Bernardinelli L, Ricevuti G, Rondanelli M: Alzheimer’s disease: From genes to nutrition. Eur J Inflamm 2014, 12, 405–414.
  7. Rodríguez-Rodríguez E, Sánchez-Juan P, Mateo I, Infante J, Sánchez-Quintana C, García-Gorostiaga I, Berciano J, Combarros O: Interaction between CD14 and LXRbeta genes modulates Alzheimer’s disease risk. J Neurol Sci 2008, 264, 97–99.
  8. Wasling P, Daborg J, Riebe I, Andersson M, Portelius E, Blennow K, Hanse E, Zetterberg H: Synaptic retrogenesis and amyloid-beta in Alzheimer’s disease. J Alzheimers Dis 2009, 16, 1–14.
  9. Maslinska D, Laure-Kamionowska M, Maslinski KT, Gujski M, Maslinski S: Distribution of tryptase-containing mast cells and metallothionein reactive astrocytes in human brains with amyloid deposits Inflamm Res 2007, 56, Suppl 1, 17–18.
  10. Landreth GE, Reed-Geaghan EG: Toll-like receptors in Alzheimer’s disease. Curr Top Microbiol Immunol 2009, 336, 137–153.
  11. Koran ME, Hohman TJ, Thornton-Wells TA: Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography. Hum Genet 2014, 133, 85–93.
  12. Toniato E, Spinas E, Saggini A, Kritas SK, Caraffa A, Antinolfi P, Saggini R, Pandolfi F, Conti P: Immunomodulatory effects of vitamin D on skin inflammation. J Biol Regul Homeost Agents 2015, 29, 563–567.
  13. Hajj HI, Eid A, Maksoud R, Jambart S, Bou Assi T, Zgheib Z, Oueidat D, Chams N, Chams S, Diab R, Barada K, Jurjus R, Cappello F, Reimund J, Kreiker J, Leone A, Jurjus A: Estrogens control inflammation in experimental colitis. J Biol Regul Homeost Agents 2014, 28, 213–224.
  14. Goth A: Effect of drugs on mast cells. Adv Pharmacol 1967, 5, 47–78.
  15. Anand P, Singh B, Jaggi AS, Singh N: Mast cells: An expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch Pharmacol 2012, 385, 657–670.
  16. Theoharides TC, Conti P, Economu M: Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. J Clin Psychopharmacol 2014, 34, 187–189.
  17. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007, 68, 1902–1908.
  18. Nakayama S, Yokote T, Hiraoka N, Nishiwaki U, Hanafusa T, Nishimura Y, Tsuji M: Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int J Immunopathol Pharmacol 2016, 19. pii: 0394632016644447 [Epub ahead of print].
  19. Caraffa A, Spinas E, Kritas SK, Lessiani G, Ronconi G, Saggini A, Antinolfi P, Pizzicannella J, Toniato E, Theoharides TC, Conti P: Endocrinology of the skin: intradermal neuroimmune network, a new frontier. J Biol Regul Homeost Agents 2016, 30, 339–343.
  20. Matin N, Tabatabaie O, Falsaperla R, Pavone P, Serra A, Cocuzza S, Di Mauro P, Licciardello L, Lubrano R, Vitaliti G: Efficacy and safety of omalizumab in paediatric age: an update of literature data. J Biol Regul Homeost Agents 2016, 30, 579–584.
  21. Eskandari N, Tashrifi F, Bastan R, Andalib A, Yousefi Z, Peachell PT: Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells. Int J Immunopathol Pharmacol 2016, 18. pii: 0394632015626150 [Epub ahead of print].
  22. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P: IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A 2010, 107, 4448–4453.
  23. Heneka MT, Carson MJ, El Khoury J: Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015, 14, 388–405.
  24. Taneo J, Adachi T, Yoshida A, Takayasu K, Takahara K, Inaba K: Amyloid β oligomers induce interleukin1β production in primary microglia in a cathepsin Band reactive oxygen species-dependent manner. Biochem Biophys Res Commun 2015, 458, 561–567.
  25. Imada A, Shijubo N, Kojima H, Abe S: Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000, 15, 1087–1093.
  26. Wang N, Liu R, Liu Y, Zhang R, He L: Sinomenine potentiates P815 cell degranulation via upregulation of Ca2+ mobilization through the Lyn/PLCγ/IP3R pathway. Int J Immunopathol Pharmacol 2015, 29. pii: 0394632015621768 [Epub ahead of print].
  27. Pałgan K, Bartuzi Z: Platelet activating factor in allergies. Int J Immunopathol Pharmacol 2015, 28, 584–589.
  28. Bañuelos-Cabrera I, Valle-Dorado MG, Aldana BI, Orozco-Suárez SA, Rocha L: Role of histaminergic system in blood-brain barrier dysfunction associated with neurological disorders. Arch Med Res 2014, 45, 677–686.
  29. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT: Release of histamine and leukotriene C4 in immediate allergic wheal reaction as measured with the microdialysis technique. Arch Dermatol Res 2000, 292, 333–340.
  30. Skuljec J, Sun H, Pul R, Bénardais K, Ragancokova D, Moharregh-Khiabani D, Kotsiari A, Trebst C, Stangel M: CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol 2011, 270, 164–171.
  31. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE: Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998, 4, 480–489.
  32. Conti P, Youinou P, Theoharides TC: Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev 2007, 6, 131–137.
  33. Schuijs MJ, Willart MA, Hammad H, Lambrecht BN: Cytokine targets in airway inflammation. Curr Opin Pharmacol 2013, 13, 351–361.
  34. Burton OT, Noval Rivas M, Zhou JS, Logsdon SL, Darling AR, Koleoglou KJ, Roers A, Houshyar H, Crackower MA, Chatila TA, Oettgen HC: Immunoglobulin E signal inhibition during allergen ingestion leads to reversal of established food allergy and induction of regulatory T cells. Immunity 2014, 41, 141–151.
  35. Sae Hoon Park, Hye-Jin Choi, So Young Lee, Joong-Soo Han: TLR4-mediated IRAK1 activation induces TNF-α expression via JNK-dependent NF-κB activation in human bronchial epithelial cells. Eur J Inflamm 2015, 13, 183–195. DOI:10.1177/1721727X15619185.
  36. Conti P, Pang X, Boucher W, Letourneau R, Reale M, Barbacane RC, Thibault J, Theoharides TC: Impact of RANTES and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997, 89, 4120–4127.
  37. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A: Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer’s pathology. J Cell Mol Med 2008, 12, 2255–2262.
  38. Zhicai Li, Jing Zhou, Dongmei Zhu, Qian Zhang, Min Huang, Yi Han, Suming Zhou: Role of endogenous TNF-α in cardiomyocyte apoptosis induced by bacteria lipoprotein and the protective effect of IL-10. Eur J Inflamm 2015, 13, 117–125. DOI:10.1177/1721727X15597363.
  39. Enoksson M, Ejendal KF, McAlpine S, Nilsson G, Lunderius-Andersson C: Human cord blood-derived mast cells are activated by the Nod1 agonist M-TriDAP to release pro-inflammatory cytokines and chemokines. J Innate Immun 2011, 3, 142–149.
  40. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J: Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia 2001, 35, 72–79.
  41. Bamberger ME, Landreth GE: Microglial interaction with beta-amyloid: Implications for the pathogenesis of Alzheimer’s disease. Microsc Res Tech 2001, 54, 59–70.
  42. Gu Y, Yang DK, Spinas E, Kritas SK, Saggini A, Caraffa A, Antinolfi P, Saggini R, Conti P: Role of TNF in mast cell neuroinflammation and pain. J Biol Regul Homeost Agents 2015, 29, 787–791.
  43. Skaper SD, Giusti P, Facci L: Microglia and mast cells: Two tracks on the road to neuroinflammation. FASEB J 2012, 26, 3103–3117.
  44. Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT: Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci 2014, 8, 315.
  45. Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, Lazarowski A, Marin M, Olloquequi J, Auladell C, Camins A: Masitinib for the treatment of mild to moderate Alzheimer’s disease. Expert Rev Neurother 2015, 15, 587–596.
  46. Nowak EC, de Vries VC, Wasiuk A, Ahonen C, Bennett KA, Le Mercier I, Ha DG, Noelle RJ: Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med 2012, 209, 2127–2135.
© Wroclaw Medical University